3.84
-0.08 (-2.04%)
| Previous Close | 3.92 |
| Open | 3.96 |
| Volume | 454,915 |
| Avg. Volume (3M) | 395,525 |
| Market Cap | 202,721,280 |
| Price / Sales | 5.89 |
| Price / Book | 28.45 |
| 52 Weeks Range | |
| Earnings Date | 12 Aug 2025 - 18 Aug 2025 |
| Profit Margin | -216.24% |
| Operating Margin (TTM) | -151.10% |
| Diluted EPS (TTM) | -1.92 |
| Quarterly Revenue Growth (YOY) | 92.60% |
| Total Debt/Equity (MRQ) | 395.59% |
| Current Ratio (MRQ) | 5.48 |
| Operating Cash Flow (TTM) | -69.98 M |
| Levered Free Cash Flow (TTM) | -46.02 M |
| Return on Assets (TTM) | -49.20% |
| Return on Equity (TTM) | -934.02% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | scPharmaceuticals Inc. | Bearish | Bearish |
AIStockmoo Score
| Analyst Consensus | -0.5 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | 0.0 |
| Average | -1.25 |
|
scPharmaceuticals Inc is a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs. The company's main product is Furoscix to treat congestion in patients with heart failure and edema in patients with chronic kidney disease. Furoscix is a novel formulation of furosemide contained in a pre-filled, Crystal Zenith cartridge and self-administered subcutaneously via a single-use, disposable, and wearable on-body delivery system. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 6.08% |
| % Held by Institutions | 77.72% |
| 52 Weeks Range | ||
| Median | 6.00 (56.25%) | |
| Total | 1 Hold | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Craig-Hallum | 26 Aug 2025 | 6.00 (56.25%) | Hold | 5.53 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |